Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$40.70 USD
-0.83 (-2.00%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $40.71 +0.01 (0.02%) 4:30 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MIRM 40.70 -0.83(-2.00%)
Will MIRM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIRM
Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates
Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
Other News for MIRM
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript
Mirum Pharmaceuticals Maintains Buy Rating with Positive Financials and Strategic Advances